The effects of levosimendan on haemodynamics in patients undergoing elective aortic valve replacement (AVR) together with coronary artery bypass grafting (CABG) surgry

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2008-001672-70-FI

Enrollment

Registered

2008-04-18

Start date

2008-05-30

Completion date

Unknown

Last updated

2014-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aortic valve dysfunction and coronary artery disease MedDRA version: 9.1 Level: LLT Classification code 10011078 Term: Coronary artery disease MedDRA version: 9.1 Level: LLT Classification code 10002916 Term: Aortic valve replacement

Interventions

Trade Name: Simdax Pharmaceutical Form: Pharmaceutical form of the placebo: Intravenous infusion Route of administration of the placebo: Intravenous use

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: ;Secondary Objective: ;Primary end point(s):	—

Countries

Finland

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026